UniQure
Delivering on the promise of gene therapy - single treatments with potentially curative result for patients with severe genetic diseases..
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $75.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1181 % | (77 %) | (94 %) | 271 % | 11 % | 120 % | 241 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 61 % | (113 %) | (3442 %) | (549 %) | (473 %) | (187 %) | 41 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 63 % | (119 %) | (4319 %) | (883 %) | (545 %) | (263 %) | (24 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 27 % | 167 % | 2941 % | 530 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
uniQure is a biotechnology company focused on developing curative gene therapies to transform the lives of patients suffering from severe genetic diseases. The company operates primarily in the healthcare and biotechnology markets, targeting conditions such as hemophilia B and Huntington's disease. uniQure's business model revolves around research and development, clinical trials, and strategic partnerships to bring their therapies to market. Revenue is generated through licensing agreements, such as their recent deal with CSL Behring, and potential future sales of approved therapies. The company serves patients, healthcare providers, and the broader medical community by offering innovative treatment options that address unmet medical needs.
Keywords: gene therapy, hemophilia B, Huntington's disease, biotechnology, healthcare, clinical trials, licensing agreements, innovative treatments, genetic diseases, patient care.
Tech stack
Investments by UniQure
Edit